Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

November 2, 2024

Study Completion Date

November 2, 2024

Conditions

Small Cell Carcinoma, Hypercalcaemic TypeOvarian Cancer

Interventions

DRUG

Pembrolizumab

Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.

Trial Locations (1)

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors

lead

University Health Network, Toronto

OTHER